Monday, April 25, 2016 6:46:04 AM
They were 100% correct for using the below Business Plan model. It fits AMBS's mantra of 'lets make it up as we go along and hype the company in efforts to entice shareholders'.
Rubinfeld was quoted at the Sept., 2014, ASM as stating "were there" regarding LymPro's launch and commercialization. Yet LymPro hasn't even achieved CLIA, let alone AMBS's 'marketing plan' and Gerald stated they were in process of almost 2 years ago. What happened to the marketing plan?
Shame on management and the BOD. IMHO, they're all despicable. In the private sector, they would all have been fired long ago:
Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy
Posted on August 10th, 2014
http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/
AJMHO
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM